After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr. Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
LISTEN TO THE PODCAST In this episode, Biorasi CEO Chris O’Brien hosted scientist and entrepreneur Daniel J. Mandell, Ph.D. to discuss how his creativity and imagination led him on a...Read More
Read Article Julianna LeMieux, PhD, Senior Science Writer at Genetic Engineering & Biotechnology News, interviewed our CEO Dan Mandell, PhD, and describes how non-standard amino acids (NSAAs) enable a new...Read More
LISTEN TO THE PODCAST CEO Dan Mandell joined Kevin Folta on the Talking Biotech Podcast for an in-depth, technical conversation on the potential of protein therapeutics. In this episode Dan...Read More
WATCH THE VIDEO GRO Biosciences CEO Dan Mandell explains how combining computation and automation enables smaller companies to innovate at a pace and scale formerly relegated to large biotechnology companies....Read More
LISTEN TO THE PODCAST In the same way that written English is built around an alphabet of just 26 letters, all life on Earth is built around a standard set...Read More
LISTEN TO THE PODCAST In this episode, we sit down with scientist and entrepreneur Daniel J. Mandell, Ph.D. Daniel is the Chief Executive Officer, Co-Founder, and Director of GRO Biosciences,...Read More
Therapeutic proteins are used to treat a wide variety of diseases, from cancer and heart disease to cystic fibrosis and diabetes. These proteins currently are produced using microbial fermentation in...Read More